On August 25th the Centers for Disease Control and Prevention (CDC) hosted a briefing on adolescent vaccination coverage. The briefing featured comments by Dr. Melinda Wharton, Deputy Director at the National Center for Immunization and Respiratory Diseases (NCIRD) at the CDC.
While immunization rates for tetanus-diphtheria-acellular pertussis (Tdap) vaccine and meningococcal vaccine saw double digit increases, Human Papillomavirus (HPV) vaccination rates increased just slightly.
In her remarks, Dr. Wharton emphasized the CDC’s disappointment in the poor adoption of the HPV vaccine. The CDC believes that the low usage of the HPV vaccine is directly linked to low awareness levels among parents as well as the lack of a strong recommendation from health care providers. Dr. Wharton suggested that CDC partners make the HPV vaccine a priority in increasing education efforts geared toward patients.
Lastly, Dr. Wharton stated that the HPV vaccine is no longer “too new” to trust it’s safety profile and consequently, both health care providers and parents should feel comfortable about the safety and efficacy of the vaccine.